Star Padcev-Keytruda Combo Expands Bladder Cancer Reach with FDA Approval, Pressuring AstraZeneca

The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. With last week’s FDA nod, Padcev and Keytruda have become the first muscle-invasive bladder cancer (MIBC) treatment that does not require considerations over the patient’s eligibility for cisplatin-based chemotherapy.